Siemens Healthcare announced FDA approval of their MAGNETOM Prisma, a 3T MRI scanner.
Siemens Healthcare announced FDA approval of their MAGNETOM Prisma, a 3T MRI scanner designed to provide high spatial and temporal resolution, particularly in highly demanding applications.
The MAGNETOM Prisma features XR Gradients, which combine 80 milliTesla per meter with a 200T-per-meter-per-second slew rate to offer a configuration unavailable in any other commercial whole-body system. The system is designed to maintain precision throughout long, demanding applications such as functional MRI. The system’s first-to-market Diffusion Spectrum Imaging (DSI) acquisition enables the user to potentially resolve fine anatomical details of the brain such as crossing white-matter fibers, the company said.
MAGNETOM Prisma’s benchmark homogeneity and advanced shimming solutions allow for finer, more effective compensation of patient-induced field disturbances. The MAGNETOM Prisma has Siemens’ Dot (Day optimizing throughput) engines that enable consistency for research applications and clinical work, the company said. The Dot engine brings automation and reproducibility to investigations across subjects, time points, and institutions.
Siemens will offer onsite upgrades to the MAGNETOM Prisma to customers who have already installed the MAGNETOM Trio.
Can MRI-Based AI Enhance Pre-Op Prediction of Tumor Deposits in Patients with Rectal Cancer?
October 31st 2024For patients with rectal cancer, an emerging nomogram that combines deep learning and clinical factors had greater than 16 percent and 23 percent increases in accuracy and specificity, respectively, for pre-op prediction of tumor deposits in comparison to clinical factors alone.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.